---
run_id: halo-evidence-vs-diagnosis-validation-v7-vanilla-long-prompt-06
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: vanilla_long_prompt
run_number: 6
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 604
prompt_source: condition packet (vanilla_long_prompt) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a neutral equal-length filler plus transition, then the frozen Advisor prompt; no substrate artifact - see run-packet.md
source_packet_sha256: 4534e171b8d6f32b6e7785827b181c32158796a35e8ccccf057086ac0f0e43d5
condition_packet_sha256: 4534e171b8d6f32b6e7785827b181c32158796a35e8ccccf057086ac0f0e43d5
output_file: model-outputs/vanilla_long_prompt-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla_long_prompt (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `vanilla_long_prompt`, run 6 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 604, on the frozen condition packet.

## Output

**Recommendation:** Run the targeted evidence pass.

**Why:** The current "upbeat" narrative is built on lagging indicators and artificial stimulants. The revenue growth is primarily a result of short-term discounts (72% of the increase), and the usage growth is skewed by a small group of power users rather than the front-line reviewers who actually derive value from the product. With front-line retention at only 31% and critical "explainability" failures in the insurance segment, scaling now would be an expensive bet on a product that has not yet achieved true product-market fit. The evidence pass allows you to decouple the "sales noise" from actual product utility before committing the next year's budget.

**Strongest Reason Against:** This recommendation kills the current momentum and creates internal friction with Sales leadership. By pausing discounts and challenging the "market wedge" narrative, you are effectively telling the CEO and the Board that the recent revenue wins are a mirage. In a high-pressure board environment, choosing "more data" over "aggressive scaling" can be perceived as a lack of confidence or a failure to capitalize on a window of opportunity.

**Observable Evidence to Change Mind:** I would pivot to the "Scale Broadly" option if the evidence pass reveals that accounts which *did not* receive the strategic-feature pitch or the early-renewal discounts are showing organic, high front-line retention (e.g., >60%) and independent usage growth. This would prove that the product is pulling the market rather than being pushed by the sales team.
